SAB Biotherapeutics Inc.
09/30/2025 | Press release | Distributed by Public on 09/30/2025 14:36
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned as members of the Board of Directors (the "Board") of SAB Biotherapeutics, Inc. (the "Company") and the size of the Board was decreased from 11 to nine, in accordance with the terms of the letter agreement entered into between the Company and RA Capital Healthcare Fund, L.P., dated July 21, 2025, in connection with the Company's July 2025 private placement of securities. The resignation of each of Ms. Hamilton and Mr. Spragens was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. The Board and the Company are deeply grateful for Ms. Hamilton's and Mr. Spragens' service, dedication, and contributions to the Company.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit Number |
Description |
|
104 |
Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document. |
SAB Biotherapeutics Inc. published this content on September 30, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 30, 2025 at 20:36 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]